相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
Heather A. Leitch et al.
LEUKEMIA RESEARCH (2018)
Thalassemia Minor and Major: Current Management
Ved Prakash Choudhry
INDIAN JOURNAL OF PEDIATRICS (2017)
Relation between chelation and clinical outcomes in lower-risk patients with patients with myelodysplastic syndromes: Registry analysis at 5 years
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2017)
Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies
Ivo Abrahama et al.
LEUKEMIA RESEARCH (2017)
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends
Maximilian Stahl et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Myelodysplastic Syndromes and Iron Chelation Therapy
Emanuele Angelucci et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
Heather A. Leitch et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Amer M. Zeidan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study
Pellegrino Musto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
How we manage iron overload in sickle cell patients
Thomas D. Coates et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies
Heather A. Leitch et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Eun-Ju Lee et al.
BLOOD REVIEWS (2016)
Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
Nicole Carreau et al.
BLOOD REVIEWS (2016)
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Amer M. Zeidan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Emerging biological therapies for the treatment of myelodysplastic syndromes
Amer M. Zeidan et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis
Katarzyna Sikorska et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2016)
New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities
Abdallah Abou Zahr et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry
Anna Waszczuk-Gajda et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Amer M. Zeidan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Current state of prognostication and risk stratification in myelodysplastic syndromes
Amer M. Zeidan et al.
CURRENT OPINION IN HEMATOLOGY (2015)
The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes
Abdallah Abou Zahr et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations
Florian Nolte et al.
LEUKEMIA RESEARCH (2015)
Iron-Induced Damage in Cardiomyopathy: Oxidative-Dependent and Independent Mechanisms
Elena Gammella et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Larissa Shamseer et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Amer M. Zeidan et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
Angel F. Remacha et al.
ANNALS OF HEMATOLOGY (2015)
The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome
Arch G. Mainous et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
Amer M. Zeidan et al.
CURRENT OPINION IN HEMATOLOGY (2014)
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
Roger M. Lyons et al.
LEUKEMIA RESEARCH (2014)
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge et al.
LEUKEMIA RESEARCH (2014)
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Prognostication in Myelodysplastic Syndromes: Beyond the International Prognostic Scoring System (IPSS)
Amer M. Zeidan et al.
AMERICAN JOURNAL OF MEDICINE (2013)
Iron Overload in Children Undergoing Cancer Treatments
Maelle de Ville de Goyet et al.
PEDIATRIC BLOOD & CANCER (2013)
Iron chelation therapy in myelodysplastic syndromes: where do we stand?
Mhairi Mitchell et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes
Amer M. Zeidan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis
Heather A. Leitch et al.
LEUKEMIA RESEARCH (2012)
Controversies surrounding iron chelation therapy for MDS
Heather A. Leitch
BLOOD REVIEWS (2011)
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices
Anastasios Raptis et al.
TRANSFUSION (2010)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Consensus statement on iron overload in myelodysplastic syndromes
John M. Bennett
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes
Luca Malcovati
LEUKEMIA RESEARCH (2007)
Elevated serum transferrin saturation and mortality
AG Mainous et al.
ANNALS OF FAMILY MEDICINE (2004)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
